Journal article
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
- Abstract:
-
Background
Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P = 0.130), and improved response rates (32% vs 14%, P = 0.059) with docetaxel plus selumetinib. NRAS status did not associate with outcome. Here, the aim was to identify novel biomarkers of response to MEKi...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Cancer Research UK
More from this funder
Bibliographic Details
- Publisher:
- Springer Nature Publisher's website
- Journal:
- British Journal of Cancer Journal website
- Volume:
- 122
- Issue:
- 4
- Pages:
- 506-516
- Publication date:
- 2020-02-18
- Acceptance date:
- 2019-11-15
- DOI:
- EISSN:
-
1532-1827
- ISSN:
-
0007-0920
- Pmid:
-
31839677
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1078864
- Local pid:
- pubs:1078864
- Deposit date:
- 2020-08-15
Terms of use
- Copyright holder:
- Gupta, A et al.
- Copyright date:
- 2020
- Rights statement:
- © The Author(s), under exclusive licence to Cancer Research UK 2019.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Springer Nature at: https://doi.org/10.1038/s41416-019-0673-5
If you are the owner of this record, you can report an update to it here: Report update to this record